Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients:A Multicentre Randomized Double-Blind Trail of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease (NEIHR)

NCT01402219 Phase 4 TERMINATED

The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with chronic kidney disease undergoing coronary angiography.

Details

Lead sponsor	Guangdong Provincial People's Hospital
Phase	Phase 4
Status	TERMINATED
Enrolment	204
Start date	2008-11
Completion	2013-05

Conditions

• Chronic Renal Disease

Interventions

• Iopamidol injection 76%
• iodixanol

Primary outcomes

• contrast-induced nephropathy — 48-72 h
  Contrast-Induced Nephropathy was defined as an increase in serum creatinine of more than 0.5 mg/dl or 25% from the baseline within 48-72 h of contrast exposure

Countries

China